Jointown Pharmaceutical Group Co Ltd
SSE:600998

Watchlist Manager
Jointown Pharmaceutical Group Co Ltd Logo
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Watchlist
Price: 5.17 CNY -0.39% Market Closed
Market Cap: ¥26.1B

EV/IC

0.6
Current
16%
Cheaper
vs 3-y average of 0.7

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
0.6
=
Enterprise Value
¥23.2B
/
Invested Capital
¥41.2B

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
0.6
=
Enterprise Value
¥23.2B
/
Invested Capital
¥41.2B

Valuation Scenarios

Jointown Pharmaceutical Group Co Ltd is trading below its 3-year average

If EV/IC returns to its 3-Year Average (0.7), the stock would be worth ¥6.16 (19% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+276%
Average Upside
142%
Scenario EV/IC Value Implied Price Upside/Downside
Current Multiple 0.6 ¥5.17
0%
3-Year Average 0.7 ¥6.16
+19%
5-Year Average 0.7 ¥6.37
+23%
Industry Average 2.1 ¥19.44
+276%
Country Average 1.9 ¥18.14
+251%

Forward EV/IC
Today’s price vs future invested capital

Not enough data available to calculate forward EV/IC

Peer Comparison

All Multiples
EV/IC
P/E
All Countries
Close

Market Distribution

Lower than 87% of companies in China
Percentile
13th
Based on 7 566 companies
13th percentile
0.6
Low
0 — 1.1
Typical Range
1.1 — 3.4
High
3.4 —
Distribution Statistics
China
Min 0
30th Percentile 1.1
Median 1.9
70th Percentile 3.4
Max 1 129 391.6

Jointown Pharmaceutical Group Co Ltd
Glance View

Market Cap
26.1B CNY
Industry
Health Care

In the sprawling landscape of the Chinese pharmaceutical industry, Jointown Pharmaceutical Group Co. Ltd. has emerged as a significant player, knitting together a vast network that facilitates the distribution of pharmaceutical products across the nation. Founded in 1999 and headquartered in Wuhan, Jointown has adeptly navigated the complexities of China's healthcare demands, becoming the country's largest privately-owned pharmaceutical wholesaler. The company’s operations span the procurement, distribution, and sale of a myriad of pharmaceutical products, medical devices, and healthcare supplies, effectively serving hospitals, clinics, and pharmacies through its extensive logistics and distribution channels. By leveraging cutting-edge technology to enhance its supply chain efficiency, Jointown ensures timely delivery and accessibility of medicines across urban and rural areas, thereby playing a pivotal role in supporting China's healthcare system. Jointown’s business model capitalizes on its robust logistical capabilities and comprehensive distribution network, which underpin its revenue streams. Through strategic partnerships with numerous domestic and international manufacturers, the company offers an impressive portfolio of pharmaceutical and healthcare products, maintaining a careful balance between proprietary and third-party offerings. This diversity in product offerings not only stabilizes its revenue base but also positions Jointown favorably in a highly competitive market. By continually expanding its e-commerce platforms and digital interfaces, the company fosters direct interaction with consumers, enhancing customer engagement and opening new revenue avenues. In essence, Jointown's prowess lies in its ability to integrate traditional distribution methods with innovative digital solutions, ensuring the company’s sustained growth and relevance in the ever-evolving pharmaceutical industry.

Intrinsic Value
19.38 CNY
Undervaluation 73%
Intrinsic Value
Price ¥5.17
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett